180 related articles for article (PubMed ID: 29959141)
1. Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases.
Kannan P; Kretzschmar WW; Winter H; Warren D; Bates R; Allen PD; Syed N; Irving B; Papiez BW; Kaeppler J; Markelc B; Kinchesh P; Gilchrist S; Smart S; Schnabel JA; Maughan T; Harris AL; Muschel RJ; Partridge M; Sharma RA; Kersemans V
Clin Cancer Res; 2018 Oct; 24(19):4694-4704. PubMed ID: 29959141
[No Abstract] [Full Text] [Related]
2. Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density.
Chen J; Chen C; Xia C; Huang Z; Zuo P; Stemmer A; Song B
Abdom Radiol (NY); 2018 Jun; 43(6):1393-1403. PubMed ID: 28939963
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
5. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
Zwick S; Strecker R; Kiselev V; Gall P; Huppert J; Palmowski M; Lederle W; Woenne EC; Hengerer A; Taupitz M; Semmler W; Kiessling F
J Magn Reson Imaging; 2009 May; 29(5):1125-33. PubMed ID: 19388117
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.
Zhang CC; Yan Z; Giddabasappa A; Lappin PB; Painter CL; Zhang Q; Li G; Goodman J; Simmons B; Pascual B; Lee J; Levkoff T; Nichols T; Xie Z
Cancer Med; 2014 Jun; 3(3):462-71. PubMed ID: 24573979
[TBL] [Abstract][Full Text] [Related]
7. Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
Tampellini M; Gned D; Baratelli C; Brizzi MP; Ottone A; Alabiso I; Bertaggia C; Di Maio M; Scagliotti GV; Veltri A
Radiol Med; 2016 Dec; 121(12):950-957. PubMed ID: 27601143
[TBL] [Abstract][Full Text] [Related]
8. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
[TBL] [Abstract][Full Text] [Related]
9. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.
Fasol U; Frost A; Büchert M; Arends J; Fiedler U; Scharr D; Scheuenpflug J; Mross K
Ann Oncol; 2012 Apr; 23(4):1030-6. PubMed ID: 21693769
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.
Kim YE; Joo B; Park MS; Shin SJ; Ahn JB; Kim MJ
Cancer Res Treat; 2016 Oct; 48(4):1210-1221. PubMed ID: 26987390
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
Muñoz NM; Minhaj AA; Maldonado KL; Kingsley CV; Cortes AC; Taghavi H; Polak U; Mitchell JM; Ensor JE; Bankson JA; Rashid A; Avritscher R
Magn Reson Imaging; 2019 Apr; 57():156-164. PubMed ID: 30465870
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.
Zhang W; Chen HJ; Wang ZJ; Huang W; Zhang LJ
Eur Radiol; 2017 May; 27(5):2086-2094. PubMed ID: 27488851
[TBL] [Abstract][Full Text] [Related]
14. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
[No Abstract] [Full Text] [Related]
15. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
[TBL] [Abstract][Full Text] [Related]
16. Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.
Consolino L; Longo DL; Sciortino M; Dastrù W; Cabodi S; Giovenzana GB; Aime S
Gastric Cancer; 2017 Jul; 20(4):629-639. PubMed ID: 27995483
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
18. Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: Preliminary results.
Yeo DM; Oh SN; Jung CK; Lee MA; Oh ST; Rha SE; Jung SE; Byun JY; Gall P; Son Y
J Magn Reson Imaging; 2015 Feb; 41(2):474-80. PubMed ID: 24375840
[TBL] [Abstract][Full Text] [Related]
19. Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.
Fleten KG; Bakke KM; Mælandsmo GM; Abildgaard A; Redalen KR; Flatmark K
Clin Exp Metastasis; 2017 Jan; 34(1):51-62. PubMed ID: 27812769
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]